In a recent Form 13F filing with the Securities and Exchange Commission, Gratus Capital LLC, a well-known hedge fund management firm, announced the acquisition of Intellia Therapeutics, adding to its impressive portfolio (SEC). According to the report, Gratus Capital paid approximately $2,348,000 for 67,311 shares of the company’s stock.
This latest move is part of Gratus Capital’s overall strategy to expand investment opportunities while diversifying its investment portfolio. Gratus Capital now owns 0.09% of Intellia Therapeutics and is well positioned to benefit from their innovative research and development efforts.
Intellia Therapeutics is a biotechnology company that specializes in gene editing, which has been described as one of medicine’s most promising areas.
Scientists can manipulate DNA at the molecular level with gene editing, which can be used to treat or even cure a variety of diseases. This technology has the potential to change the way we approach healthcare issues around the world.
Despite recent setbacks that resulted in lower stock prices for NTLA, investors remain optimistic about Intellia Therapeutics’ future prospects due to their cutting-edge technology and world-class team of experts.
NTLA traded up $0.17 to $35.96 per share on the NASDAQ exchange during midday trading on Friday, with an average trading volume of over one million shares per day. The stock had a fifty-day moving average of $39.73 and a 200-day moving average of $44.07, with an all-time high of $76.45 per share.
To stay up to date on developments at Intellia Therapeutics or other hedge funds that own NTLA, go to HoldingsChannel.com, where you can find information on insider trades and all recent filings with regulatory bodies such as the SEC.
Gratus Capital LLC’s brilliant moves in its investment portfolio demonstrate that it stays on top of market trends and has a keen eye for spotting opportunities that will yield positive returns. We can only wait and see Gratus Capital LLC come up with more mysterious but lucrative deals as the company continues to add exciting prospects to its investment portfolio.
